The GSK3A Knockout SK-HEP-1 Polyclonal Cells provide a CRISPR/Cas9-edited population of human SK-HEP-1 cells with loss-of-function mutations at the GSK3A locus. This polyclonal knockout pool, rather than a clonal isolate, offers a representative mixture of edited genotypes, minimizing clonal bias while enabling robust interrogation of GSK3A-dependent signaling.
SK-HEP-1 is a human liver adenocarcinoma cell line originally isolated from the ascitic fluid of a patient with adenocarcinoma of the liver. It displays epithelial morphology and is commonly employed as a hepatocellular carcinoma (HCC) model. Though widely used, SK-HEP-1 has been reported to express some endothelial markers, which should be considered when interpreting results in the context of hepatic cell biology.
GSK3A encodes glycogen synthase kinase 3 alpha, a constitutively active serine/threonine kinase that phosphorylates glycogen synthase (GYS1) and ??-catenin (CTNNB1). In the Wnt pathway, GSK3A resides in the destruction complex with AXIN, APC, and other scaffold proteins; it phosphorylates ??-catenin, targeting it for ubiquitination and proteasomal degradation. Wnt ligands inhibit GSK3A through Dishevelled (DVL) and FRAT1, leading to ??-catenin stabilization, nuclear translocation, and activation of TCF/LEF target genes such as MYC, CCND1, and JUN, as well as regulators of EMT like SNAI1. AKT-mediated phosphorylation at Ser21 inactivates GSK3A downstream of insulin and PI3K/AKT, linking growth factor signaling to glycogen metabolism and cell survival. Through these interactions, GSK3A modulates proliferation, differentiation, and apoptosis, with additional regulatory inputs from PP2A phosphatase and pathway crosstalk with Hedgehog and Notch signaling.
Within SK-HEP-1 cells, aberrant activation of Wnt/??-catenin signaling is a hallmark of hepatocellular carcinoma, often driving unchecked proliferation and evasion of apoptosis. By disrupting GSK3A expression, this knockout model relieves the constitutive repression of ??-catenin, resulting in elevated levels of ??-catenin and constitutive transcription of oncogenic targets. This mimics the molecular events seen in a subset of liver cancers with CTNNB1 mutations or loss of negative regulators, making it a valuable system to study tumor biology, metastasis, and epithelial-mesenchymal transition in the hepatic context.
Researchers can use this polyclonal knockout population to study Wnt/??-catenin transcriptional programs via TOP/FOP Flash luciferase reporter assays, or to quantify target gene expression (MYC, CCND1) by RT-qPCR. Protein-level validation includes western blotting for total and phospho-GSK3A (Ser21), while immunofluorescence visualizes ??-catenin nuclear accumulation. Functional readouts such as MTT proliferation and Annexin V/PI apoptosis assays assess cell growth and death. The model is also amenable to investigating crosstalk with PI3K/AKT and Hedgehog pathways or screening small-molecule inhibitors. For further information or to discuss custom applications, please contact Ascent Research.
